OraSure Technologies received 510(k) clearance from the FDA for an at-home urine sample collection kit compatible with Roche molecular systems for STI testing. The Colli-Pee kit supports first-void self-collection and downstream lab-based testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. The clearance expands the infrastructure for remote specimen collection and could broaden access to testing programs by letting providers order molecular STI panels that start with patient home collection. In parallel, Dermasensor obtained CE mark approval for a handheld skin cancer detection device using spectroscopy and AI to assess suspicious lesions in real time at the point of care, supporting Europe’s growing footprint of algorithmic dermatology tools.